273 related articles for article (PubMed ID: 33453943)
1. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy.
Ivashko-Pachima Y; Gozes I
Prog Mol Biol Transl Sci; 2021; 177():65-90. PubMed ID: 33453943
[TBL] [Abstract][Full Text] [Related]
2. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.
Ivashko-Pachima Y; Maor-Nof M; Gozes I
PLoS One; 2019; 14(3):e0213666. PubMed ID: 30865715
[TBL] [Abstract][Full Text] [Related]
3. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.
Ivashko-Pachima Y; Sayas CL; Malishkevich A; Gozes I
Mol Psychiatry; 2017 Sep; 22(9):1335-1344. PubMed ID: 28115743
[TBL] [Abstract][Full Text] [Related]
4. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
Gozes I
Curr Pharm Des; 2011; 17(31):3413-7. PubMed ID: 21902667
[TBL] [Abstract][Full Text] [Related]
5. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
Shiryaev N; Pikman R; Giladi E; Gozes I
Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979
[TBL] [Abstract][Full Text] [Related]
6. SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism.
Ivashko-Pachima Y; Ganaiem M; Ben-Horin-Hazak I; Lobyntseva A; Bellaiche N; Fischer I; Levy G; Sragovich S; Karmon G; Giladi E; Shazman S; Barak B; Gozes I
Mol Psychiatry; 2022 Aug; 27(8):3316-3327. PubMed ID: 35538192
[TBL] [Abstract][Full Text] [Related]
7. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins.
Oz S; Kapitansky O; Ivashco-Pachima Y; Malishkevich A; Giladi E; Skalka N; Rosin-Arbesfeld R; Mittelman L; Segev O; Hirsch JA; Gozes I
Mol Psychiatry; 2014 Oct; 19(10):1115-24. PubMed ID: 25178163
[TBL] [Abstract][Full Text] [Related]
8. Tauopathy in the young autistic brain: novel biomarker and therapeutic target.
Grigg I; Ivashko-Pachima Y; Hait TA; Korenková V; Touloumi O; Lagoudaki R; Van Dijck A; Marusic Z; Anicic M; Vukovic J; Kooy RF; Grigoriadis N; Gozes I
Transl Psychiatry; 2020 Jul; 10(1):228. PubMed ID: 32661233
[TBL] [Abstract][Full Text] [Related]
9. ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration.
Gozes I; Ivashko-Pachima Y
Front Aging Neurosci; 2015; 7():205. PubMed ID: 26578950
[TBL] [Abstract][Full Text] [Related]
10. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.
Oz S; Ivashko-Pachima Y; Gozes I
PLoS One; 2012; 7(12):e51458. PubMed ID: 23272107
[TBL] [Abstract][Full Text] [Related]
11. A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP.
Ivashko-Pachima Y; Gozes I
Front Cell Neurosci; 2019; 13():435. PubMed ID: 31632241
[TBL] [Abstract][Full Text] [Related]
12. A novel davunetide (NAPVSIPQQ to NAPVSIPQE) point mutation in activity-dependent neuroprotective protein (ADNP) causes a mild developmental syndrome.
Gozes I; Shazman S
Eur J Neurosci; 2023 Jul; 58(2):2641-2652. PubMed ID: 36669790
[TBL] [Abstract][Full Text] [Related]
13. The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse.
Sragovich S; Malishkevich A; Piontkewitz Y; Giladi E; Touloumi O; Lagoudaki R; Grigoriadis N; Gozes I
Transl Psychiatry; 2019 Jan; 9(1):2. PubMed ID: 30664622
[TBL] [Abstract][Full Text] [Related]
14. Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory.
Amram N; Hacohen-Kleiman G; Sragovich S; Malishkevich A; Katz J; Touloumi O; Lagoudaki R; Grigoriadis NC; Giladi E; Yeheskel A; Pasmanik-Chor M; Jouroukhin Y; Gozes I
Mol Psychiatry; 2016 Oct; 21(10):1467-76. PubMed ID: 26782054
[TBL] [Abstract][Full Text] [Related]
15. Novel ADNP Syndrome Mice Reveal Dramatic Sex-Specific Peripheral Gene Expression With Brain Synaptic and Tau Pathologies.
Karmon G; Sragovich S; Hacohen-Kleiman G; Ben-Horin-Hazak I; Kasparek P; Schuster B; Sedlacek R; Pasmanik-Chor M; Theotokis P; Touloumi O; Zoidou S; Huang L; Wu PY; Shi R; Kapitansky O; Lobyntseva A; Giladi E; Shapira G; Shomron N; Bereswill S; Heimesaat MM; Grigoriadis N; McKinney RA; Rubinstein M; Gozes I
Biol Psychiatry; 2022 Jul; 92(1):81-95. PubMed ID: 34865853
[TBL] [Abstract][Full Text] [Related]
16. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
Vulih-Shultzman I; Pinhasov A; Mandel S; Grigoriadis N; Touloumi O; Pittel Z; Gozes I
J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885
[TBL] [Abstract][Full Text] [Related]
17. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
Gozes I
Biol Chem; 2016 Mar; 397(3):177-84. PubMed ID: 25955282
[TBL] [Abstract][Full Text] [Related]
18. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).
Magen I; Gozes I
Neuropeptides; 2013 Dec; 47(6):489-95. PubMed ID: 24210139
[TBL] [Abstract][Full Text] [Related]
19. Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease.
Gozes I
J Neurosci Res; 2017 Jan; 95(1-2):652-660. PubMed ID: 27870441
[TBL] [Abstract][Full Text] [Related]
20. The ADNP Syndrome and CP201 (NAP) Potential and Hope.
Gozes I
Front Neurol; 2020; 11():608444. PubMed ID: 33329371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
